Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Abbott Park, Illinois Tuesday, January 27, 2026, 13:00 Hrs [IST] ...
Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline ...
14d
PainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research
TAMPA, Fla., Jan. 13, 2026 /PRNewswire/ -- PainTEQ, a medical device company dedicated to advancing minimally invasive solutions for sacroiliac (SI) joint dysfunction, today announced the appointment ...
Abbott Laboratories ABT is slated to report fourth-quarter 2025 results on Jan. 22, before the opening bell. The company ...
The MarketWatch News Department was not involved in the creation of this content. Real-time insights reveal BIOTRONIK Neuro's remote monitoring with remote programming led to high rates of therapy use ...
Background Spinal cord stimulation (SCS) has become a cornerstone of neuromodulatory interventions for chronic pain, offering ...
Neuroscientists have used a nanosized sensor to record spinal cord neurons in free-moving mice, a feat that could lead to the development of better treatments for spinal cord disease and injury.
School is back in session for the pupils and teachers of Abbott Elementary after a much-needed winter break. After learning some not-so good news about the state of the school, the Abbott crew is ...
In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...
In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device to treat moderate to severe major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results